Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tong Hua Dong Bao Insulin To Compete With Novo Nordisk, Eli Lilly

This article was originally published in PharmAsia News

Executive Summary

Tong Hua Dong Bao Pharmaceutical projected its 2009 output of recombinant human insulin at 3,000 Kg and aims to compete with Novo Nordisk and Eli Lilly domestically and internationally. Tong Hua Dong Bao invested RMB 600 million in facility expansions, and with the increased output it expects to boost its market share in China 50 percent. In addition, relevant national agencies have tested the quality of Tong Hua Dong Bao's insulin and reported it to be similar to that of Novo Nordisk and Eli Lilly. Tong Hua Dong Bao's product is also at least 30 percent cheaper giving the Chinese company a competitive advantage in the international market. Tong Hua Dong Bao has started targeting affluent oil-producing countries in the Middle East as potential customers. (Click here for more

You may also be interested in...

Warning Letter Close-Outs – October 2020

The US FDA issued only one device-related close-out letter in October.

Compounding Pharmacies Sue FDA For Conflating Out-Of-State Dispensing And Distribution In MOU

Seven pharmacies have filed a lawsuit against the FDA claiming the agency exceeded its statutory authority in its final standard memorandum of understanding on interstate compounding and that the MOU will have an adverse impact on compounding pharmacies and patients.

What COVID Spotlight Means For Pharma – In Their Own Words

Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem. 




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts